LITFARMA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,851,320 | 2,195,924 | 2,803,541 | 3,015,803 | 2,769,707 | 2,845,644 | 2,630,531 | 3,570,251 |
| Profit before tax | 89,292 | 146,171 | 219,627 | 9,032 | 5,900 | 10,532 | 6,406 | 10,472 |
| Net profit | 84,789 | 139,653 | 210,054 | 8,183 | 5,413 | 8,993 | 5,067 | 8,800 |
| Equity | 223,219 | 362,872 | 572,926 | 581,109 | 586,522 | 595,515 | 600,582 | 609,382 |
| Liabilities | 721,876 | 759,079 | 608,885 | 646,513 | 718,913 | 794,101 | 815,461 | 741,969 |
| Non-current assets | 9,861 | 44,903 | 119,228 | 118,053 | 104,632 | 124,295 | 103,434 | 137,212 |
| Current assets | 933,692 | 1,075,085 | 1,061,002 | 1,108,801 | 1,199,960 | 1,262,878 | 1,310,060 | 1,211,646 |
| Total assets | 943,553 | 1,119,988 | 1,180,230 | 1,226,854 | 1,304,592 | 1,387,173 | 1,413,494 | 1,348,858 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 153,964 | 10,241 | 163,178 |
| Social insurance contributions | - | - | - | - | - | 49,025 | 49,140 | 38,564 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -1.0% | +18.6% | +27.7% | +7.6% | -8.2% | +2.7% | -7.6% | +35.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 9.0% | 12.5% | 17.8% | 0.7% | 0.4% | 0.6% | 0.4% | 0.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 38.0% | 38.5% | 36.7% | 1.4% | 0.9% | 1.5% | 0.8% | 1.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 4.6% | 6.4% | 7.5% | 0.3% | 0.2% | 0.3% | 0.2% | 0.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 4.8% | 6.7% | 7.8% | 0.3% | 0.2% | 0.4% | 0.2% | 0.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 3.2 | 2.1 | 1.1 | 1.1 | 1.2 | 1.3 | 1.4 | 1.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 149,099 | 195,193 | 300,380 | 306,693 | 270,215 | 367,180 | 399,576 | 714,050 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
LITFARMA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-07-18 | 2023-07-20 | 3358.08 |
LITFARMA - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
LITFARMA, UAB (code 133943714) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of EUR 3.57 million, up 35.7% year on year and 25.5% over two years. Net profit was EUR 8.8 thousand, compared with EUR 5.1 thousand in 2024 and EUR 9.0 thousand in 2023, indicating a low but stable profitability profile. The 2025 net profit margin was 0.2%. Balance sheet size remained broadly stable, with total assets of EUR 1.35 million, equity of EUR 609.4 thousand and liabilities of EUR 742.0 thousand. Long-term assets increased to EUR 137.2 thousand, while short-term assets stood at EUR 1.21 million. Key performance indicators for 2025 show ROE of 1.4%, ROA of 0.7%, debt-to-equity of 1.22 and asset turnover of 2.65x. Revenue per employee reached EUR 714.0 thousand, while profit per employee was EUR 1.8 thousand, reflecting a high-volume trading business with thin margins.